Abstract 2065P
Background
Beyond the diagnosis, multiple situations during the natural history of cancer can be pointed out as stressful and hard to convey. The first Medical Oncology appointment is crucial and comprehensive, where patients are invited to understand their diagnosis and grasp the prognostic consequences of cancer and its treatment. Strategies to elicit information while meeting patients’ needs are required to overcome the potentially challenging moment, improve clinical outcomes and promote safe, high-quality, patient-centred care. This study evaluated the communication preferences at the first medical oncology approach.
Methods
A total of 169 cancer patients from a Portuguese Medical Oncology department answered the C-FAQ (Communication in first medical oncology appointment questionnaire), a survey representing the SPIKES and MPP (Measure of Patients’ Preferences) protocols asking about preferences regarding Content (what and how much information is told), Facilitation (where and when the information is conveyed), and Support (emotional support during the interaction) elements of communication and patient’s assign to these items.
Results
The Content elements (M=3.69, SD=0.35) were mentioned as the most important when compared with Facilitation (M=3.56, SD=0.39), t(30.13) = 17.38, p < .001, or Support (M=3.46, SD=0.44), t(24.14) = 7.12 p < .001. The physician’s knowledge, honesty and being given clear information about cancer and treatment were the areas of greatest importance. Facilitation was considered more important than Support, t(24.14) = 16.42, p < .001. Globally, all items were mostly evaluated as “very important”, Mdn 65.85% (11.525).
Conclusions
All communication components should be considered during the dialogue in this context. Medical teams should overcome barriers by learning skills to communicate with patients and promote engagement. More research is required to understand the complexity of the triad patient, physician, and family and address how patients’ preferences can be met in a demanding clinical atmosphere.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Professor Doutor Fernando Fonseca.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06